May 16playeuropeanrouletteonlineforfree, announced on the official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China, ABBVplayeuropeanrouletteonlineforfree.US) SubmitplayeuropeanrouletteonlineforfreeUpadacitinib tablets are intended to be included in the breakthrough treatment varieties and are intended to treat adolescent and adult patients with non-segmental vitiligo aged 12 and older. According to public information, upadacitinib's Chinese common name is Uparatinib Sustained-Release Tablets. It is a JAK inhibitor that has been previously approved in China for treatment of various other indications. According to AbbVie's official website, the indication of upatinib sustained release tablets for the treatment of vitiligo is currently in the Phase 3 clinical study stage.
It is reported that upatinib sustained release tablets are a selective JAK inhibitor. Previous studies have shown that this product has greater inhibitory efficacy on JAK1 than on JAK2, JAK3 and TYK2. In China, upatinib sustained release tablets have been previously approved for the treatment of multiple indications, including atopic dermatitis, rheumatoid arthritis, active psoriatic arthritis, ulcerative colitis, Crohn's disease, active radiologically negative axial spondylitis (nr-axSpA), active ankylosing spondylitis (AS), etc.
